Millennium Pharmaceuticals Inc. and Kyowa Hakko Kirin Co. | Date: 2015-03-10
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.
Millennium Pharmaceuticals Inc. | Date: 2015-10-12
The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
Millennium Pharmaceuticals Inc. | Date: 2015-01-13
The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R
Millennium Pharmaceuticals Inc. | Date: 2015-10-09
Disclosed is a compound of formula (I): crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an E1 activating enzyme, particularly NAE, including, e.g., cancer.
Millennium Pharmaceuticals Inc. | Date: 2015-06-30
Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, R